Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial-Reference-Cited by-同舟云学术

Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial

Published:2022-12 Issue:12 Volume:22 Page:1716-1727
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Lazarus Rajeka,Querton Benedicte,Corbic Ramljak Irena,Dewasthaly Shailesh,Jaramillo Juan Carlos,Dubischar Katrin,Krammer Michael,Weisova Petronela,Hochreiter Romana,Eder-Lingelbach Susanne,Taucher Christian,Finn Adam,Bethune Claire,Boffito Marta,Bula Marcin,Burns Fiona M,Clark Rebecca,Dasyam Dileep,Drysdale Simon,Faust Saul,Gkrania-Klotsas Effrossyni,Green Christopher,Hassanin Hana,Heath Paul,Heer Amardeep,Helliwell Toby,Hormis Anil,Kalra Philip,Lazarus Rajeka,Moran Ed,Ndikum John,Page Iain,Price David,Probert Nick,Ramjee Mahadev,Rampling Tommy,Randeva Harpal S,Ryder Stephen,Steer John,Thompson Emma,Torku David

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference24 articles.

1. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial;Al Kaabi;JAMA,2021

2. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial;Xia;Lancet Infect Dis,2021

3. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial;Zhang;Lancet Infect Dis,2021

4. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile;Bueno;Clin Infect Dis,2021

5. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: an interim analysis in Indonesia;Fadlyana;Vaccine,2021

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant compared with Boostrix in healthy adults and adolescents;Vaccine;2024-10

2. Boosting the immune response in COVID-19 vaccines via an Alum:CpG complex adjuvant;Antiviral Research;2024-09

3. SARS-CoV-2 Antibody Level after Homologous and Heterologous Booster Vaccines: an 18-month Longitudinal Observational Cohort Study in Indonesia;The Open Public Health Journal;2024-07-31

4. COVID-19: vaccination, therapeutics and a review of the science and public health;Annals of Medicine & Surgery;2024-07-17

5. Exploring future perspectives and pipeline progression in vaccine research and development;ANN IG MED PREV COMU;2024